2-(4-Chlorophenoxy)-2-methylpropanoic acid
| Title | Journal |
|---|---|
| Effects of clofibric acid alone and in combination with 17β-estradiol on mRNA abundance in primary hepatocytes isolated from rainbow trout. | Toxicology in vitro : an international journal published in association with BIBRA 20140901 |
| Tissue-specific 5' heterogeneity of PPARα transcripts and their differential regulation by leptin. | PloS one 20130101 |
| Transition metal modified and partially calcined inorganic-organic pillared clays for the adsorption of salicylic acid, clofibric acid, carbamazepine, and caffeine from water. | Journal of colloid and interface science 20121115 |
| The role of microbial adaptation and biodegradable dissolved organic carbon on the attenuation of trace organic chemicals during groundwater recharge. | The Science of the total environment 20121015 |
| Interactions of acidic pharmaceuticals with human serum albumin: insights into the molecular toxicity of emerging pollutants. | Amino acids 20121001 |
| Photochemical fate of a mixture of emerging pollutants in the presence of humic substances. | Water research 20121001 |
| Effects of effluent organic matter characteristics on the removal of bulk organic matter and selected pharmaceutically active compounds during managed aquifer recharge: Column study. | Journal of contaminant hydrology 20121001 |
| Impact of the auxin signaling inhibitor p-chlorophenoxyisobutyric acid on short-term Cd-induced hydrogen peroxide production and growth response in barley root tip. | Journal of plant physiology 20120915 |
| Photocatalytic decomposition of crotamiton over aqueous TiO(2) suspensions: determination of intermediates and the reaction pathway. | Chemosphere 20120901 |
| Hormonal and chemical regulation of paraoxonases in mice. | The Journal of pharmacology and experimental therapeutics 20120901 |
| Assessment of possible carcinogenicity of oxyfluorfen to humans using mode of action analysis of rodent liver effects. | Toxicological sciences : an official journal of the Society of Toxicology 20120801 |
| Evaluation of aquatic plants for removing polar microcontaminants: a microcosm experiment. | Chemosphere 20120801 |
| Batch versus continuous feeding strategies for pharmaceutical removal by subsurface flow constructed wetland. | Environmental pollution (Barking, Essex : 1987) 20120801 |
| Distribution and temporal evolution of pharmaceutically active compounds alongside sewage sludge treatment. Risk assessment of sludge application onto soils. | Journal of environmental management 20120715 |
| Effects of pharmaceuticals on the expression of genes involved in detoxification in a carp primary hepatocyte model. | Environmental science & technology 20120605 |
| Solar regeneration of powdered activated carbon impregnated with visible-light responsive photocatalyst: factors affecting performances and predictive model. | Water research 20120601 |
| Additive effects of clofibric acid and pyruvate dehydrogenase kinase isoenzyme 4 (PDK4) deficiency on hepatic steatosis in mice fed a high saturated fat diet. | The FEBS journal 20120501 |
| Pharmaceutical removal in tropical subsurface flow constructed wetlands at varying hydraulic loading rates. | Chemosphere 20120401 |
| The PPARα agonists fenofibrate and CP-778875 cause increased β-oxidation, leading to oxidative injury in skeletal and cardiac muscle in the rat. | Toxicologic pathology 20120401 |
| Adsorptive removal of naproxen and clofibric acid from water using metal-organic frameworks. | Journal of hazardous materials 20120330 |
| Suspended biofilm carrier and activated sludge removal of acidic pharmaceuticals. | Water research 20120315 |
| Uptake of organic emergent contaminants in spath and lettuce: an in vitro experiment. | Journal of agricultural and food chemistry 20120227 |
| Analysis of endocrine disrupting compounds, pharmaceuticals and personal care products in sewage sludge by gas chromatography-mass spectrometry. | Talanta 20120130 |
| Differential induction of stearoyl-CoA desaturase 1 and 2 genes by fibrates in the liver of rats. | Biological & pharmaceutical bulletin 20120101 |
| The effectiveness of sewage treatment processes to remove faecal pathogens and antibiotic residues. | Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering 20120101 |
| Malignant ovarian tumors with induced expression of carbonyl reductase show spontaneous regression. | Clinical Medicine Insights. Oncology 20120101 |
| Analysis of anti-inflammatory, analgesic, stimulant and antidepressant drugs in purified water from wastewater treatment plants using SPE-LC tandem mass spectrometry. | Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering 20120101 |
| PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials. | PPAR research 20120101 |
| Impact of solid retention time and nitrification capacity on the ability of activated sludge to remove pharmaceuticals. | Environmental technology 20120101 |
| Removal of pharmaceuticals in biologically treated wastewater by chlorine dioxide or peracetic acid. | Environmental technology 20120101 |
| Induction of 1-acylglycerophosphocholine acyltransferase genes by fibrates in the liver of rats. | Biological & pharmaceutical bulletin 20120101 |
| Microextraction by packed sorbent for the analysis of pharmaceutical residues in environmental water samples by in situ derivatization-programmed temperature vaporizer-gas chromatography-mass spectrometry. | Journal of chromatography. A 20111230 |
| Adsorption of clofibric acid and ketoprofen onto powdered activated carbon: effect of natural organic matter. | Environmental technology 20111201 |
| Ecotoxicological impacts of clofibric acid and diclofenac in common carp (Cyprinus carpio) fingerlings: hematological, biochemical, ionoregulatory and enzymological responses. | Journal of hazardous materials 20111115 |
| Organically functionalized mesoporous SBA-15 as sorbents for removal of selected pharmaceuticals from water. | Journal of hazardous materials 20111015 |
| Can pharmaceuticals interfere with the synthesis of active androgens in male fish? An in vitro study. | Marine pollution bulletin 20111001 |
| Effects of clofibric acid on the biliary excretion of benoxaprofen glucuronide and taurine conjugate in rats. | Die Pharmazie 20111001 |
| Cork-based activated carbons as supported adsorbent materials for trace level analysis of ibuprofen and clofibric acid in environmental and biological matrices. | Journal of chromatography. A 20110916 |
| In situ aqueous derivatization and determination of non-steroidal anti-inflammatory drugs by salting-out-assisted liquid-liquid extraction and gas chromatography-mass spectrometry. | Journal of chromatography. A 20110916 |
| Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARα antagonists. | Bioorganic & medicinal chemistry letters 20110815 |
| Reactive tracer test to evaluate the fate of pharmaceuticals in rivers. | Environmental science & technology 20110801 |
| Fulvic acid affects proliferation and maturation phases in Abies cephalonica embryogenic cells. | Journal of plant physiology 20110715 |
| Monitoring of pharmaceutically active compounds on the Guadalquivir River basin (Spain): occurrence and risk assessment. | Journal of environmental monitoring : JEM 20110701 |
| UV and VUV photolysis vs. UV/H2O2 and VUV/H2O2, treatment for removal of clofibric acid from aqueous solution. | Environmental technology 20110701 |
| Simultaneous determination of 20 pharmacologically active substances in cow's milk, goat's milk, and human breast milk by gas chromatography-mass spectrometry. | Journal of agricultural and food chemistry 20110511 |
| Comparison of four extraction methods for the analysis of pharmaceuticals in wastewater. | Journal of chromatography. A 20110506 |
| Auxin: a major player in the shoot-to-root regulation of root Fe-stress physiological responses to Fe deficiency in cucumber plants. | Plant physiology and biochemistry : PPB 20110501 |
| Assessment of the occurrence and distribution of pharmaceuticals in a Mediterranean wetland (L'Albufera, Valencia, Spain) by LC-MS/MS. | Analytical and bioanalytical chemistry 20110501 |
| Nitrification activity and community structure of nitrite-oxidizing bacteria in the bioreactors operated with addition of pharmaceuticals. | Journal of hazardous materials 20110415 |
| Fate of organic micropollutants in the hyporheic zone of a eutrophic lowland stream: results of a preliminary field study. | The Science of the total environment 20110415 |
| Decrease of hepatic stellate cells in rats with enhanced sensitivity to clofibrate-induced hepatocarcinogenesis. | Cancer science 20110401 |
| Occurrence and behavior of non-steroidal anti-inflammatory drugs and lipid regulators in wastewater and urban river water of the Pearl River Delta, South China. | Journal of environmental monitoring : JEM 20110401 |
| Vibrational spectra and natural bond orbital analysis of the herbicidal molecule 2(4-chlorophenoxy)-2-methyl propionic acid. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20110201 |
| Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20110101 |
| Clofibric acid increases the formation of oleic acid in endoplasmic reticulum of the liver of rats. | Journal of pharmacological sciences 20110101 |
| Transcription of DWARF4 plays a crucial role in auxin-regulated root elongation in addition to brassinosteroid homeostasis in Arabidopsis thaliana. | PloS one 20110101 |
| Exposure of the main italian river basin to pharmaceuticals. | Journal of toxicology 20110101 |
| Alert-QSAR. Implications for electrophilic theory of chemical carcinogenesis. | International journal of molecular sciences 20110101 |
| The value of repeating studies and multiple controls: replicated 28-day growth studies of rainbow trout exposed to clofibric acid. | Environmental toxicology and chemistry 20101201 |
| Triglycerides and gallstone formation. | Clinica chimica acta; international journal of clinical chemistry 20101111 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Human health risk assessment of pharmaceuticals in water: issues and challenges ahead. | International journal of environmental research and public health 20101101 |
| Identification of the UDP-glucuronosyltransferase responsible for bucolome N-glucuronide formation in rats. | Die Pharmazie 20101101 |
| Fibrates plus betaine: a winning combination? | The New Zealand medical journal 20101015 |
| Rapid resolution liquid chromatography-tandem mass spectrometry method for the determination of endocrine disrupting chemicals (EDCs), pharmaceuticals and personal care products (PPCPs) in wastewater irrigated soils. | Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes 20101001 |
| Case report. Hyperlipoproteinaemia(a): which is the optimal therapy? A case report. | Journal of clinical pharmacy and therapeutics 20101001 |
| Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. | The American journal of medicine 20101001 |
| Effects of fibrates on cardiovascular outcomes. | Lancet (London, England) 20100925 |
| Effects of fibrates on cardiovascular outcomes. | Lancet (London, England) 20100925 |
| Liverbeads: a practical and relevant in vitro model for gene induction investigations. | Drug metabolism and disposition: the biological fate of chemicals 20100901 |
| Beyond statin therapy: a review of the management of residual risk in diabetes mellitus. | Journal of the Royal Society of Medicine 20100901 |
| Lipid-lowering agents and new onset diabetes mellitus. | Expert opinion on pharmacotherapy 20100801 |
| Management of hypertriglyceridemia in the diabetic patient. | Current diabetes reports 20100801 |
| PPARalpha: an emerging therapeutic target in diabetic microvascular damage. | Nature reviews. Endocrinology 20100801 |
| Assessment of plant-driven removal of emerging organic pollutants by duckweed. | Chemosphere 20100801 |
| Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. | Current opinion in lipidology 20100801 |
| Physiological interactions of antiauxins with auxin in roots. | Journal of plant physiology 20100715 |
| Occurrence and risk assessment of acidic pharmaceuticals in the Yellow River, Hai River and Liao River of north China. | The Science of the total environment 20100715 |
| [On behalf and the extent of evidence]. | Revue medicale suisse 20100609 |
| Multi-residue method for the analysis of pharmaceutical compounds in sewage sludge, compost and sediments by sonication-assisted extraction and LC determination. | Journal of separation science 20100601 |
| Fibrates consistently lower risk of cardiovascular events across high-risk groups. | Cardiovascular journal of Africa 20100601 |
| Occurrence and a screening-level risk assessment of human pharmaceuticals in the Pearl River system, South China. | Environmental toxicology and chemistry 20100601 |
| Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. | Lancet (London, England) 20100529 |
| Fibrates in CVD: a step towards personalised medicine. | Lancet (London, England) 20100529 |
| Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials. | International journal of cardiology 20100528 |
| Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. | Pediatric blood & cancer 20100501 |
| Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome. | Current clinical pharmacology 20100501 |
| The effect of structure and a secondary carbon source on the microbial degradation of chlorophenoxy acids. | Chemosphere 20100501 |
| Fibrates, glitazones, and peroxisome proliferator-activated receptors. | Arteriosclerosis, thrombosis, and vascular biology 20100501 |
| Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome. | Postgraduate medicine 20100501 |
| Determination of pharmaceuticals in soils and sediments by pressurized liquid extraction and liquid chromatography tandem mass spectrometry. | Journal of chromatography. A 20100416 |
| Investigating the mechanism of clofibric acid removal in Fe(0)/H2O systems. | Journal of hazardous materials 20100415 |
| Clofibric acid degradation in UV254/H2O2 process: effect of temperature. | Journal of hazardous materials 20100415 |
| Dynamics and attenuation of acidic pharmaceuticals along a river stretch. | Environmental science & technology 20100415 |
| [Global therapy of diabetic dyslipidemia: benefits and new therapeutic approaches]. | Medicina clinica 20100403 |
| Removal of pharmaceuticals from water: using liquid-core microcapsules as a novel approach. | Water research 20100401 |
| Orthopaedic/radiology/pathology conference: Multiple nodular outgrowths in the hands and feet of a 60-year-old man. | Clinical orthopaedics and related research 20100201 |
| Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling. | Toxicology in vitro : an international journal published in association with BIBRA 20100201 |
| Removal of pharmaceuticals in microcosm constructed wetlands using Typha spp. and LECA. | Bioresource technology 20100201 |
| [HDL and CETP in atherogenesis]. | Deutsche medizinische Wochenschrift (1946) 20100201 |
| Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. | The American journal of medicine 20100201 |
| Ecotoxicity assessment of lipid regulators in water and biologically treated wastewater using three aquatic organisms. | Environmental science and pollution research international 20100101 |
| Application of the combination index (CI)-isobologram equation to study the toxicological interactions of lipid regulators in two aquatic bioluminescent organisms. | Water research 20100101 |
| Management of hypertriglyceridaemia caused by combination antiretroviral therapy in HIV-infected patients: role of omega-3 polyunsaturated fatty acids at different dosages, compared with fibrates. | International journal of STD & AIDS 20100101 |
| Oxidation of atenolol, propranolol, carbamazepine and clofibric acid by a biological Fenton-like system mediated by the white-rot fungus Trametes versicolor. | Water research 20100101 |
| Discussion by Reinhard Länge et al. on 'Degradation of the endocrine disrupting chemicals (EDCs) carbamazepine, clofibric acid, and iopromide by corona discharge over water' by Krause et al. [Chemosphere 75(2) (2009) 163-168]. | Chemosphere 20100101 |
| Apolipoprotein B, diabetes and medical consensus. | Annals of clinical biochemistry 20100101 |
| Photocatalytic degradation of clofibric acid, carbamazepine and iomeprol using conglomerated TiO2 and activated carbon in aqueous suspension. | Water science and technology : a journal of the International Association on Water Pollution Research 20100101 |
| Antivascular therapy for epithelial ovarian cancer. | Journal of oncology 20100101 |
| Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists induce constitutive androstane receptor (CAR) and cytochrome P450 2B in rat primary hepatocytes. | Drug metabolism and pharmacokinetics 20100101 |
| Liquid chromatography with post-column reagent addition of ammonia in methanol coupled to negative ion electrospray ionization tandem mass spectrometry for determination of phenoxyacid herbicides and their degradation products in surface water. | Analytical chemistry insights 20100101 |
| [Lipid therapy in patients with diabetes]. | Wiener medizinische Wochenschrift (1946) 20100101 |
| PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. | Nuclear receptor signaling 20100101 |
| Sex-different hepaticglycogen content and glucose output in rats. | BMC biochemistry 20100101 |
| Methods of chromatographic determination of medicines decreasing the level of cholesterol. | Acta poloniae pharmaceutica 20100101 |
| PRIC295, a Nuclear Receptor Coactivator, Identified from PPARα-Interacting Cofactor Complex. | PPAR research 20100101 |
| Peroxisome proliferator-activated receptor alpha target genes. | PPAR research 20100101 |
| Effects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism. | PPAR research 20100101 |
| Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver. | PPAR research 20100101 |
| Fate of selected pharmaceuticals and personal care products after secondary wastewater treatment processes in Taiwan. | Water science and technology : a journal of the International Association on Water Pollution Research 20100101 |
| Maternal influences on the transmission of leukocyte gene expression profiles in population samples from Brisbane, Australia. | PloS one 20100101 |
| Molecular Pharmacology of Kidney and Inner Ear CLC-K Chloride Channels. | Frontiers in pharmacology 20100101 |
| Glucose sensing neurons in the ventromedial hypothalamus. | Sensors (Basel, Switzerland) 20100101 |
| Identification of intermediates and assessment of ecotoxicity in the oxidation products generated during the ozonation of clofibric acid. | Journal of hazardous materials 20091230 |
| Effects of lipid-lowering pharmaceuticals bezafibrate and clofibric acid on lipid metabolism in fathead minnow (Pimephales promelas). | Environmental toxicology and chemistry 20091201 |
| Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients? | Fundamental & clinical pharmacology 20091201 |
| Functional role of neuroendocrine-specific protein-like 1 in membrane translocation of GLUT4. | Diabetes 20091201 |
| Combination therapy of statins and fibrates in the management of cardiovascular risk. | Current opinion in lipidology 20091201 |
| Novel targets that affect high-density lipoprotein metabolism: the next frontier. | The American journal of cardiology 20091116 |
| The characteristics of enriched nitrifier culture in the degradation of selected pharmaceutically active compounds. | Journal of hazardous materials 20091115 |
| Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3. | Journal of medicinal chemistry 20091112 |
| Degradation and adsorption of selected pharmaceuticals and personal care products (PPCPs) in agricultural soils. | Chemosphere 20091101 |
| Lipid disorders. | JAAPA : official journal of the American Academy of Physician Assistants 20091101 |
| A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants. | Environmental health perspectives 20091101 |
| Application of dynamic liquid-phase microextraction and injection port derivatization combined with gas chromatography-mass spectrometry to the determination of acidic pharmaceutically active compounds in water samples. | Journal of chromatography. A 20091030 |
| Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression. | Biochemical and biophysical research communications 20091030 |
| New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function. | Journal of medicinal chemistry 20091022 |
| Synthesis and biological evaluation of 2-heteroarylthioalkanoic acid analogues of clofibric acid as peroxisome proliferator-activated receptor alpha agonists. | Journal of medicinal chemistry 20091022 |
| Review article: nuclear receptors and liver disease--current understanding and new therapeutic implications. | Alimentary pharmacology & therapeutics 20091015 |
| Subacute exposure to N-ethyl perfluorooctanesulfonamidoethanol results in the formation of perfluorooctanesulfonate and alters superoxide dismutase activity in female rats. | Archives of toxicology 20091001 |
| Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine. | Toxicology in vitro : an international journal published in association with BIBRA 20091001 |
| Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. | Cardiovascular drugs and therapy 20091001 |
| Prevention of local lipotoxicity: a new renoprotective mechanism of peroxisome proliferator-activated receptor-alpha activation in hypertension and obesity? | Hypertension research : official journal of the Japanese Society of Hypertension 20091001 |
| Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. | The American journal of medicine 20091001 |
| Calcium-induced calcium release in skeletal muscle. | Physiological reviews 20091001 |
| Peroxisome proliferators attenuate free arachidonic acid pool in the kidney through inducing lysophospholipid acyltransferases. | Journal of pharmacological sciences 20091001 |
| A clinical puzzle: fibrates and homocysteine elevation: editorial to: 'fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine' by M. Lever et al. | Cardiovascular drugs and therapy 20091001 |
| [Place of fibrates for the treatment of patients with atherogenic dyslipidemia]. | Revue medicale de Liege 20091001 |
| Ozonation of clofibric acid catalyzed by titanium dioxide. | Journal of hazardous materials 20090930 |
| Adsorptive removal of selected pharmaceuticals by mesoporous silica SBA-15. | Journal of hazardous materials 20090915 |
| Probing the fibrate binding specificity of rat liver fatty acid binding protein. | Journal of medicinal chemistry 20090910 |
| Leachability of some emerging contaminants in reclaimed municipal wastewater-irrigated turf grass fields. | Environmental toxicology and chemistry 20090901 |
| Dyslipidemia and cardiovascular risk: the importance of early prevention. | QJM : monthly journal of the Association of Physicians 20090901 |
| Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. | Current opinion in cardiology 20090901 |
| Factors modulating fibrates response: therapeutic implications and alternative strategies. | Endocrine, metabolic & immune disorders drug targets 20090901 |
| Myopathy with statin-fibrate combination therapy: clinical considerations. | Nature reviews. Endocrinology 20090901 |
| Fibrate therapy and renal function. | Current atherosclerosis reports 20090901 |
| The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia. | Journal of clinical hypertension (Greenwich, Conn.) 20090901 |
| Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice. | Biochimica et biophysica acta 20090801 |
| Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20090801 |
| Occurrence of selected pharmaceuticals in an agricultural landscape, western Lake Erie basin. | Water research 20090801 |
| Advances in the medical treatment of diabetic retinopathy. | Diabetes care 20090801 |
| Single and combined toxicity of pharmaceuticals and personal care products (PPCPs) on the rainbow trout liver cell line RTL-W1. | Aquatic toxicology (Amsterdam, Netherlands) 20090726 |
| [HDL-cholesterol: from risk factor to therapeutic target]. | Medicina clinica 20090711 |
| Iatrogenic severe depression of high-density lipoprotein cholesterol. | Journal of clinical pharmacology 20090701 |
| Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. | Current opinion in cardiology 20090701 |
| Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease. | Pharmacological research 20090701 |
| Effects of WY-14643 on peroxisomal enzyme activity and hormone secretion in immortalized human trophoblast cells. | Biological & pharmaceutical bulletin 20090701 |
| [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy]. | Klinische Monatsblatter fur Augenheilkunde 20090701 |
| Analysis of selected pharmaceutical compounds and endocrine disruptors in municipal wastewater using solid-phase microextraction and gas chromatography. | Water environment research : a research publication of the Water Environment Federation 20090701 |
| Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model. | The Journal of biological chemistry 20090612 |
| Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. | Clinical endocrinology 20090601 |
| Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. | Current medical research and opinion 20090601 |
| Comment on 'Oxidative degradation of organic compounds using zero-valent iron in the presence of natural organic matter serving as an electron shuttle'. | Environmental science & technology 20090515 |
| Analysis of differential gene expression in colorectal cancer and stroma using fluorescence-activated cell sorting purification. | British journal of cancer 20090505 |
| Antiplatelet actions of statins and fibrates are mediated by PPARs. | Arteriosclerosis, thrombosis, and vascular biology 20090501 |
| In vitro genotoxic assessment of xenobiotic diacylglycerols in an in vitro micronucleus assay. | Environmental and molecular mutagenesis 20090501 |
| Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome. | Diabetes, obesity & metabolism 20090501 |
| Statin islands and PPAR ligands in platelets. | Arteriosclerosis, thrombosis, and vascular biology 20090501 |
| [Diabetic dyslipoproteinemia: beyond LDL]. | Deutsche medizinische Wochenschrift (1946) 20090501 |
| Anatase vs. rutile efficiency on the photocatalytic degradation of clofibric acid under near UV to visible irradiation. | Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology 20090501 |
| Fibrates in the chemical action of daunorubicin. | Current cancer drug targets 20090501 |
| Degradation of the endocrine disrupting chemicals (EDCs) carbamazepine, clofibric acid, and iopromide by corona discharge over water. | Chemosphere 20090401 |
| Occurrence and removal of pharmaceuticals in a municipal sewage treatment system in the south of Sweden. | The Science of the total environment 20090401 |
| Water quality improvement in a full-scale tertiary constructed wetland: effects on conventional and specific organic contaminants. | The Science of the total environment 20090401 |
| Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet. | Pancreas 20090401 |
| Automated potentiometric titrations in KCl/water-saturated octanol: method for quantifying factors influencing ion-pair partitioning. | Analytical chemistry 20090401 |
| Interpreting clinical trials of diabetic dyslipidaemia: new insights. | Diabetes, obesity & metabolism 20090301 |
| Differential regulation of peroxisome proliferator-activated receptor (PPAR)-alpha1 and truncated PPARalpha2 as an adaptive response to fasting in the control of hepatic peroxisomal fatty acid beta-oxidation in the hibernating mammal. | Endocrinology 20090301 |
| Lipid management in the geriatric patient. | Endocrinology and metabolism clinics of North America 20090301 |
| Activation of PPARalpha and PPARgamma reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1. | European journal of pharmacology 20090301 |
| Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile. | European journal of internal medicine 20090301 |
| The use of lipid-lowering drug therapy in children and adolescents. | Current opinion in investigational drugs (London, England : 2000) 20090301 |
| Free-radical-induced oxidative and reductive degradation of fibrate pharmaceuticals: kinetic studies and degradation mechanisms. | The journal of physical chemistry. A 20090219 |
| Properties of an oral preparation containing a chitosan salt. | Molecules (Basel, Switzerland) 20090213 |
| Toxicity and removal efficiency of pharmaceutical metabolite clofibric acid by Typha spp.--potential use for phytoremediation? | Bioresource technology 20090201 |
| Ability of white-rot fungi to remove selected pharmaceuticals and identification of degradation products of ibuprofen by Trametes versicolor. | Chemosphere 20090201 |
| Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies. | Nature clinical practice. Cardiovascular medicine 20090201 |
| Hyperlipidaemia and cardiovascular disease: nonlipid-lowering effects of omega-3 fatty acids, statins and fibrates. | Current opinion in lipidology 20090201 |
| Fibrates: where are we now? | Therapeutic advances in cardiovascular disease 20090201 |
| On the road to better dyslipidemia outcomes. | The Nurse practitioner 20090201 |
| Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort). | The American journal of cardiology 20090201 |
| Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. | Journal of the American College of Cardiology 20090127 |
| A new respirometric endpoint-based biosensor to assess the relative toxicity of chemicals on immobilized human cells. | Ecotoxicology and environmental safety 20090101 |
| Determination of phenolic endocrine disrupting chemicals and acidic pharmaceuticals in surface water of the Pearl Rivers in South China by gas chromatography-negative chemical ionization-mass spectrometry. | The Science of the total environment 20090101 |
| Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins? | Angiology 20090101 |
| HIV-1 infection and the PPARγ-dependent control of adipose tissue physiology. | PPAR research 20090101 |
| The effects of medications used for the management of dyslipidemia on postprandial lipemia. | Current medicinal chemistry 20090101 |
| Anti-inflammatory effects of fibrates: an overview. | Current medicinal chemistry 20090101 |
| Fibrates and microvascular complications in diabetes--insight from the FIELD study. | Current pharmaceutical design 20090101 |
| Fibrates but not statins increase plasma selenium in dyslipidemic aged patients--the EVA study. | Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 20090101 |
| Thermodynamics of lipophilic drug binding to intestinal fatty acid binding protein and permeation across membranes. | Molecular pharmaceutics 20090101 |
| Impact of sample acquisition and linear amplification on gene expression profiling of lung adenocarcinoma: laser capture micro-dissection cell-sampling versus bulk tissue-sampling. | BMC medical genomics 20090101 |
| Etofibrate enhances 123I-LDL-binding in human liver. | Hellenic journal of nuclear medicine 20090101 |
| [Fibrate-induced deterioration of renal function]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101 |
| PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer. | PPAR research 20090101 |
| Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs. | PPAR research 20090101 |
| Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. | PloS one 20090101 |
| Identifying patients with metabolic syndrome. | The Practitioner 20090101 |
| [Treatment of dyslipidemia in patients with metabolic syndrome and chronic kidney disease]. | Vnitrni lekarstvi 20090101 |
| Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. | Vascular health and risk management 20090101 |
| Serum and erythrocyte membrane phospholipids fatty acid composition in hyperlipidemia: effects of dietary intervention and combined diet and fibrate therapy. | General physiology and biophysics 20090101 |
| Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver. | Lipids in health and disease 20090101 |
| Photo-degradation of clofibric acid by ultraviolet light irradiation at 185 nm. | Water science and technology : a journal of the International Association on Water Pollution Research 20090101 |
| Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. | PloS one 20090101 |
| Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. | PloS one 20090101 |
| Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design. | Journal of medicinal chemistry 20081225 |
| A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. | The American journal of cardiology 20081222 |
| 2-Methyl-2-(4-nitro-phen-oxy)propanoic acid. | Acta crystallographica. Section E, Structure reports online 20081201 |
| Influence of pharmaceutical residues on the structure of activated sludge bacterial communities in wastewater treatment bioreactors. | Water research 20081101 |
| When high is low: raising low levels of high-density lipoprotein cholesterol. | Current cardiology reports 20081101 |
| The role of triglycerides in cardiovascular risk. | Current cardiology reports 20081101 |
| Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. | Postgraduate medical journal 20081101 |
| Substituted tertiary phosphine Ru(II) organometallics: catalytic utility on the hydrolysis of etofibrate in pharmaceuticals. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20081001 |
| Behaviour and biomarkers of oxidative stress in Gambusia holbrooki after acute exposure to widely used pharmaceuticals and a detergent. | Ecotoxicology and environmental safety 20081001 |
| HDL therapy for cardiovascular diseases: the road to HDL mimetics. | Current atherosclerosis reports 20081001 |
| Selective determination of acidic pharmaceuticals in wastewater using molecularly imprinted solid-phase extraction. | Analytica chimica acta 20080926 |
| PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease. | Diabetes, obesity & metabolism 20080901 |
| Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. | Nature clinical practice. Cardiovascular medicine 20080901 |
| CEPHEUS Trial. | Archives of cardiovascular diseases 20080901 |
| Assessment of lipid-lowering treatment in France--the CEPHEUS study. | Archives of cardiovascular diseases 20080901 |
| Simultaneous determination of pharmaceuticals, endocrine disrupting compounds and hormone in soils by gas chromatography-mass spectrometry. | Journal of chromatography. A 20080822 |
| Effects of fibrates, anti-inflammatory drugs and antidepressants in the fish hepatoma cell line PLHC-1: cytotoxicity and interactions with cytochrome P450 1A. | Toxicology in vitro : an international journal published in association with BIBRA 20080801 |
| Therapy and clinical trials: metabolic syndrome and cardiovascular risk management. | Current opinion in lipidology 20080801 |
| A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy. | Acta cardiologica 20080801 |
| [Clock genes regulate circadian rhythm of lipid metabolism and infarction]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20080801 |
| Colchicine: serious interactions. | Prescrire international 20080801 |
| Simvastatin with or without ezetimibe in familial hypercholesterolemia. | The New England journal of medicine 20080731 |
| [New trends in lipidology: the increasing role of HDL-cholesterol]. | Orvosi hetilap 20080727 |
| Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. | Swiss medical weekly 20080726 |
| [Effectiveness of cardiometabolic risk reduction in patients with type 1 diabetes mellitus]. | Orvosi hetilap 20080706 |
| Species-specific kinetics and zonation of hepatic DNA synthesis induced by ligands of PPARalpha. | Toxicological sciences : an official journal of the Society of Toxicology 20080701 |
| Occurrence of steroid estrogens, endocrine-disrupting phenols, and acid pharmaceutical residues in urban riverine water of the Pearl River Delta, South China. | The Science of the total environment 20080701 |
| Bibliography. Current world literature. HDL cholesterol. | Current opinion in cardiology 20080701 |
| Managing dyslipidemia in chronic kidney disease. | Journal of the American College of Cardiology 20080624 |
| Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. | The American journal of cardiology 20080615 |
| Role of the p50 subunit of NF-kappaB in vitamin E-induced changes in mice treated with the peroxisome proliferator, ciprofibrate. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20080601 |
| Administration of ciprofibrate to lactating mothers induces PPARalpha-signaling pathway in the liver and kidney of suckling rats. | Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20080601 |
| Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. | Heart (British Cardiac Society) 20080601 |
| Using liquid chromatography-ion trap mass spectrometry to determine pharmaceutical residues in Taiwanese rivers and wastewaters. | Chemosphere 20080601 |
| Diabetic dyslipidemia: a practical guide to therapy. | The Journal of family practice 20080601 |
| Statin-fibrate combination therapy. | The American journal of cardiology 20080515 |
| Behaviour of pharmaceutical products and biodegradation intermediates in horizontal subsurface flow constructed wetland. A microcosm experiment. | The Science of the total environment 20080501 |
| Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. | European journal of pharmacology 20080428 |
| Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials. | The American journal of cardiology 20080417 |
| Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. | The American journal of cardiology 20080417 |
| Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. | The American journal of cardiology 20080417 |
| Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. | The Journal of biological chemistry 20080411 |
| Differential effects of fibrates on the metabolic activation of 2-phenylpropionic acid in rats. | Drug metabolism and disposition: the biological fate of chemicals 20080401 |
| Presence and some characteristics of peroxisomes in immortalized human trophoblast cells. | Biological & pharmaceutical bulletin 20080401 |
| Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. | Journal of cardiovascular pharmacology 20080401 |
| Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms. | Trends in cardiovascular medicine 20080401 |
| Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates. | Acta cardiologica 20080401 |
| [Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy]. | Giornale italiano di cardiologia (2006) 20080401 |
| HDL-C in post-menopausal women: An important therapeutic target. | International journal of cardiology 20080314 |
| Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists. | Bioorganic & medicinal chemistry 20080301 |
| Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. | International journal of cardiology 20080227 |
| First-line therapies for lowering triglyceride levels. | American family physician 20080215 |
| Effects of pharmaceutically active compounds on a mixed microbial community originating from a municipal wastewater treatment plant. | Environmental science & technology 20080215 |
| Ciglitazone induces caspase-independent apoptosis via p38-dependent AIF nuclear translocation in renal epithelial cells. | Toxicology 20080203 |
| Organic micropollutant removal in a full-scale surface flow constructed wetland fed with secondary effluent. | Water research 20080201 |
| Individual and mixture effects of selected pharmaceuticals and personal care products on the marine phytoplankton species Dunaliella tertiolecta. | Archives of environmental contamination and toxicology 20080201 |
| The treatment of dyslipidemia--what's left in the pipeline? | ChemMedChem 20080201 |
| Quantitative analysis of auxin-regulated proteins from basal part of leaf sheaths in rice by two-dimensional difference gel electrophoresis. | Phytochemistry 20080201 |
| Multiple benign symmetric lipomatosis--a differential diagnosis of obesity: is there a rationale for fibrate treatment? | Obesity surgery 20080201 |
| Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents. | Climacteric : the journal of the International Menopause Society 20080201 |
| Drugs for lipids. | Treatment guidelines from the Medical Letter 20080201 |
| Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. | Clinical therapeutics 20080201 |
| Synthesis of polymeric thiazolidinedione and fibrate conjugates. | Archives of pharmacal research 20080201 |
| Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio? | Current atherosclerosis reports 20080201 |
| Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? | Arteriosclerosis, thrombosis, and vascular biology 20080101 |
| A role for IAA in the infection of Arabidopsis thaliana by Orobanche aegyptiaca. | Annals of botany 20080101 |
| Peroxisome proliferator-activated receptor alpha agonists enhance cardiomyogenesis of mouse ES cells by utilization of a reactive oxygen species-dependent mechanism. | Stem cells (Dayton, Ohio) 20080101 |
| P-chlorophenoxyisobutyric acid impairs auxin response for gravity-regulated peg formation in cucumber (Cucumis sativus) seedlings. | Journal of plant research 20080101 |
| Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice. | Toxicological sciences : an official journal of the Society of Toxicology 20080101 |
| Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? | Thrombosis research 20080101 |
| Chylomicronemia and the chylomicronemia syndrome: a practical approach to management. | The American journal of medicine 20080101 |
| Optimal management of combined dyslipidemia: what have we behind statins monotherapy? | Advances in cardiology 20080101 |
| Update on the treatment of diabetic retinopathy. | TheScientificWorldJournal 20080101 |
| Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention. | Diabetes/metabolism research and reviews 20080101 |
| Fibrate-associated adverse effects beyond muscle and liver toxicity. | Current pharmaceutical design 20080101 |
| Treatment of high-risk older persons with lipid-lowering drug therapy. | American journal of therapeutics 20080101 |
| Fibrate therapy: an update. | Cardiology in review 20080101 |
| Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. | Drug safety 20080101 |
| Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha. | Advances in experimental medicine and biology 20080101 |
| Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. | Lipids in health and disease 20080101 |
| Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats. | Arzneimittel-Forschung 20080101 |
| The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products. | PPAR research 20080101 |
| Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key? | PPAR research 20080101 |
| Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth. | PPAR research 20080101 |
| Therapeutic effects of fibrates in postprandial lipemia. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20080101 |
| [Raising HDL cholesterol: which is the best strategy?]. | Revista da Associacao Medica Brasileira (1992) 20080101 |
| Removal of selected pharmaceuticals by chlorination, coagulation-sedimentation and powdered activated carbon treatment. | Water science and technology : a journal of the International Association on Water Pollution Research 20080101 |
| Non invasive in vivo investigation of hepatobiliary structure and function in STII medaka (Oryzias latipes): methodology and applications. | Comparative hepatology 20080101 |
| Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study. | BMC clinical pharmacology 20080101 |
| Determination of etofibrate, fenofibrate, and atorvastatin in pharmaceutical preparations and plasma using differential pulse polarographic and square wave voltammetric techniques. | Journal of AOAC International 20080101 |
| The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. | Reviews in cardiovascular medicine 20080101 |
| 2-Methyl-2-(4-nitro-phenyl-sulfanyl)-propanoic acid. | Acta crystallographica. Section E, Structure reports online 20080101 |
| High-density lipoprotein metabolism: potential therapeutic targets. | The American journal of cardiology 20071203 |
| Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. | Postepy higieny i medycyny doswiadczalnej (Online) 20071203 |
| Fibrate therapy: safety considerations. | Current opinion in lipidology 20071201 |
| Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. | Circulation journal : official journal of the Japanese Circulation Society 20071201 |
| A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia. | International journal of STD & AIDS 20071201 |
| Atherosclerosis in type 2 diabetes: a role for fibrate therapy? | Diabetes & vascular disease research 20071201 |
| Bridging the gap in treatment options for patients with hypertriglyceridemia. | The Journal of family practice 20071201 |
| Behavior of selected priority organic pollutants in horizontal subsurface flow constructed wetlands: a preliminary screening. | Chemosphere 20071101 |
| Evaluation of UV irradiation for photolytic and oxidative degradation of pharmaceutical compounds in water. | Water research 20071101 |
| High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. | Pharmacoepidemiology and drug safety 20071101 |
| Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). | Arteriosclerosis, thrombosis, and vascular biology 20071101 |
| Genetic characterization of mutants resistant to the antiauxin p-chlorophenoxyisobutyric acid reveals that AAR3, a gene encoding a DCN1-like protein, regulates responses to the synthetic auxin 2,4-dichlorophenoxyacetic acid in Arabidopsis roots. | Plant physiology 20071101 |
| The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. | American heart journal 20071101 |
| Measuring biomarkers to assess the therapeutic effects of PPAR agonists? | Pharmacogenomics 20071101 |
| [Adverse effects of lipid-lowering medications]. | Nihon rinsho. Japanese journal of clinical medicine 20071028 |
| [Drug-induced myopathies]. | Nihon rinsho. Japanese journal of clinical medicine 20071028 |
| Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer. | Oncology reports 20071001 |
| Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways. | Chemical research in toxicology 20071001 |
| Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20071001 |
| FPIN's clinical inquiries. Best alternatives to statins for treating hyperlipidemia. | American family physician 20071001 |
| Atherosclerosis and cardiovascular risk reduction with PPAR agonists. | Current atherosclerosis reports 20071001 |
| Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. | Toxicology and applied pharmacology 20070915 |
| Treating hypertriglyceridemia. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20070911 |
| Treating hypertriglyceridemia. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20070911 |
| Treating hypertriglyceridemia. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20070911 |
| Is it time to stop treating dyslipidaemia with fibrates? | The New Zealand medical journal 20070907 |
| Clinical practice. Hypertriglyceridemia. | The New England journal of medicine 20070906 |
| The mode of action of thidiazuron: auxins, indoleamines, and ion channels in the regeneration of Echinacea purpurea L. | Plant cell reports 20070901 |
| Characterization of 1-aminocyclopropane-1-carboxylate (ACC) deaminase containing Methylobacterium oryzae and interactions with auxins and ACC regulation of ethylene in canola (Brassica campestris). | Planta 20070901 |
| Diethylnitrosamine initiation does not alter clofibric acid-induced hepatocarcinogenesis in the rat. | Toxicological sciences : an official journal of the Society of Toxicology 20070901 |
| Preliminary studies into the effects of the human pharmaceutical Clofibric acid on sperm parameters in adult Fathead minnow. | Aquatic toxicology (Amsterdam, Netherlands) 20070815 |
| Liquid chromatography-(tandem) mass spectrometry for the follow-up of the elimination of persistent pharmaceuticals during wastewater treatment applying biological wastewater treatment and advanced oxidation. | Journal of chromatography. A 20070810 |
| The acyl-CoA thioesterase I is regulated by PPARalpha and HNF4alpha via a distal response element in the promoter. | Journal of lipid research 20070801 |
| Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. | Journal of lipid research 20070801 |
| CEC enantioseparations on chiral monolithic columns: a study of the stereoselective degradation of (R/S)-dichlorprop [2-(2,4-dichlorophenoxy)propionic acid] in soil. | Electrophoresis 20070801 |
| Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. | Journal of clinical epidemiology 20070801 |
| Strategies for reducing cardiovascular risk in patients with hypertriglyceridemia. | The Journal of family practice 20070801 |
| [Intervention for hypertriglyceridemia]. | Nihon rinsho. Japanese journal of clinical medicine 20070728 |
| [Intervention study for elevating high density lipoprotein cholesterol level]. | Nihon rinsho. Japanese journal of clinical medicine 20070728 |
| [Role of fibrate in cardiovascular disease prevention]. | Nihon rinsho. Japanese journal of clinical medicine 20070728 |
| Selection of a support matrix for the removal of some phenoxyacetic compounds in constructed wetlands systems. | The Science of the total environment 20070715 |
| Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology. | European journal of pharmacology 20070712 |
| Expression and characterization of cytochrome P450 2X1 in channel catfish (Ictalurus punctatus). | Biochimica et biophysica acta 20070701 |
| Effect of chrysin and natural coumarins on UGT1A1 and 1A6 activities in rat and human hepatocytes in primary culture. | Planta medica 20070701 |
| Analytical development for analysis of pharmaceuticals in water samples by SPE and GC-MS. | Analytical and bioanalytical chemistry 20070601 |
| [Metabolically designed treatments: from biochemistry to the vessel lining]. | La Revue de medecine interne 20070601 |
| Elimination of selected acidic pharmaceuticals from municipal wastewater by an activated sludge system and membrane bioreactors. | Environmental science & technology 20070515 |
| Studies on the metabolism of tolmetin to the chemically reactive acyl-coenzyme A thioester intermediate in rats. | Drug metabolism and disposition: the biological fate of chemicals 20070501 |
| Management of hypertriglyceridemia. | American family physician 20070501 |
| The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. | Current medical research and opinion 20070501 |
| Determination of anti-inflammatory drugs and estrogens in water by HPLC with UV detection. | Journal of separation science 20070501 |
| Hypertriglyceridemia and cardiovascular risk reduction. | Clinical therapeutics 20070501 |
| Hypertriglyceridemia: its etiology, effects and treatment. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20070410 |
| P450 CYP2C epoxygenase and CYP4A omega-hydroxylase mediate ciprofibrate-induced PPARalpha-dependent peroxisomal proliferation. | Journal of lipid research 20070401 |
| Stearoyl-CoA desaturase activity is elevated by the suppression of its degradation by clofibric acid in the liver of rats. | Journal of pharmacological sciences 20070401 |
| The role of PPAR-alpha agonists in the prevention of CVD in diabetes. | Current diabetes reports 20070401 |
| Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. | Molecular cancer therapeutics 20070401 |
| [IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology]. | Arquivos brasileiros de cardiologia 20070401 |
| Aqueous in situ derivatization of carboxylic acids by an ionic carbodiimide and 2,2,2-trifluoroethylamine for electron-capture detection. | Journal of chromatography. A 20070323 |
| Expert commentary: the safety of fibrates in lipid-lowering therapy. | The American journal of cardiology 20070319 |
| Safety considerations with fibrate therapy. | The American journal of cardiology 20070319 |
| Statins and the risk of pneumonia: a population-based, nested case-control study. | Pharmacotherapy 20070301 |
| Fibrates: what have we learned in the past 40 years? | Pharmacotherapy 20070301 |
| Fibrates upregulate TRB3 in lymphocytes independent of PPAR alpha by augmenting CCAAT/enhancer-binding protein beta (C/EBP beta) expression. | Molecular immunology 20070201 |
| LC-MS analysis and environmental risk of lipid regulators. | Analytical and bioanalytical chemistry 20070201 |
| Analysis of pharmaceuticals in wastewater and removal using a membrane bioreactor. | Analytical and bioanalytical chemistry 20070201 |
| Removal of pharmaceutical residues in a pilot wastewater treatment plant. | Analytical and bioanalytical chemistry 20070201 |
| Ultrastructural effects of pharmaceuticals (carbamazepine, clofibric acid, metoprolol, diclofenac) in rainbow trout (Oncorhynchus mykiss) and common carp (Cyprinus carpio). | Analytical and bioanalytical chemistry 20070201 |
| Human pharmaceuticals, antioxidants, and plasticizers in wastewater treatment plant and water reclamation plant effluents. | Water environment research : a research publication of the Water Environment Federation 20070201 |
| High performance liquid chromatographic determination of etofibrate and its hydrolysis products. | Journal of pharmaceutical and biomedical analysis 20070104 |
| Simultaneous quantification of polycyclic aromatic hydrocarbons (PAHs), polychlorinated biphenyls (PCBs), and pharmaceuticals and personal care products (PPCPs) in Mississippi river water, in New Orleans, Louisiana, USA. | Chemosphere 20070101 |
| Degradation of clofibric acid in acidic aqueous medium by electro-Fenton and photoelectro-Fenton. | Chemosphere 20070101 |
| Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. | Diabetic medicine : a journal of the British Diabetic Association 20070101 |
| A light- and electron-microscope study of hepatocytes of rats fed different diets. | Comptes rendus biologies 20070101 |
| Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes. | American journal of therapeutics 20070101 |
| Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20070101 |
| Advances in swine transcriptomics. | International journal of biological sciences 20070101 |
| Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype. | American journal of therapeutics 20070101 |
| [Molecular pharmacology and medicinal chemistry of fibrate]. | Pharmazie in unserer Zeit 20070101 |
| [Fibrate in lipid metabolism disorders]. | Pharmazie in unserer Zeit 20070101 |
| Clofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents. | BMC pharmacology 20070101 |
| [Fibrates and markers of inflammation]. | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20070101 |
| [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]. | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20070101 |
| [Pleiotropic effects of fibric acid derivatives (Lipanthyl-200) among patients with metabolic syndrome]. | Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20070101 |
| Dyslipidemia as a risk factor for erectile dysfunction. | Current medicinal chemistry 20070101 |
| Pharmacoenvironmentology--a component of pharmacovigilance. | Environmental health : a global access science source 20070101 |
| Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. | Advances in therapy 20070101 |
| Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. | Clinical drug investigation 20070101 |
| An investigation of the effects of lipid-lowering medications: genome-wide linkage analysis of lipids in the HyperGEN study. | BMC genetics 20070101 |
| [When should an association of lipid-lowering drugs be proposed in a patient failing to reach therapeutic targets under monotherapy? Guidelines of the New French Society of Atherosclerosis]. | Archives des maladies du coeur et des vaisseaux 20070101 |
| Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors. | Clinical cornerstone 20070101 |
| Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. | The American heart hospital journal 20070101 |
| Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia. | HIV clinical trials 20070101 |
| [Therapy of dyslipidemia in post-infarction: state of the art]. | La Clinica terapeutica 20070101 |
| Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors. | PPAR research 20070101 |
| [Analysis of dietary habits and dietary intake in hypertensive smokers]. | Przeglad lekarski 20070101 |
| Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. | Clinical cornerstone 20070101 |
| Hypertriglyceridemia and cardiovascular disease management. | Journal of the American Academy of Nurse Practitioners 20070101 |
| [Fibrate and its perspective as a drug for metabolic syndrome]. | Nihon rinsho. Japanese journal of clinical medicine 20061228 |
| Aryloxoalcanoic compounds induce resistance to antibiotic therapy in urinary tract infection caused by Escherichia coli. | FEMS immunology and medical microbiology 20061201 |
| Regulation of hepatic cholesterol synthesis by a novel protein (SPF) that accelerates cholesterol biosynthesis. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20061201 |
| [Favorable effects of decreasing lipids in patients with diabetes mellitus]. | Deutsche medizinische Wochenschrift (1946) 20061201 |
| Fibrates after the FIELD study: Some answers, more questions. | Diabetes & vascular disease research 20061201 |
| Management of hyperlipidemia with statins in the older patient. | Clinical interventions in aging 20061201 |
| [New indications and therapeutic objectives for dyslipidemia]. | Atencion primaria 20061130 |
| 9-cis beta-carotene-rich powder of the alga Dunaliella bardawil increases plasma HDL-cholesterol in fibrate-treated patients. | Atherosclerosis 20061101 |
| Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. | Hepatology (Baltimore, Md.) 20061101 |
| 20-HETE and salt-sensitivity of blood pressure a novel emerging concept. | American journal of hypertension 20061101 |
| Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) induces cell death through MAPK-dependent mechanism in osteoblastic cells. | Toxicology and applied pharmacology 20060901 |
| Nucleophilic group transfer reactivity for fibric acid derived drug molecules. | Journal of pharmaceutical sciences 20060901 |
| Fibrate therapy in patients with metabolic syndrome and diabetes mellitus. | Current atherosclerosis reports 20060901 |
| A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis. | The American journal of pathology 20060901 |
| Seasonality effects on pharmaceuticals and s-triazine herbicides in wastewater effluent and surface water from the Canadian side of the upper Detroit River. | Environmental toxicology and chemistry 20060901 |
| The interference of pharmaceuticals with endogenous and xenobiotic metabolizing enzymes in carp liver: an in-vitro study. | Environmental science & technology 20060815 |
| Cloning, tissue expression, and regulation of beagle dog CYP4A genes. | Toxicological sciences : an official journal of the Society of Toxicology 20060801 |
| Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. | Current opinion in lipidology 20060801 |
| Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy. | Coronary artery disease 20060801 |
| Clofibrate treatment promotes branched-chain amino acid catabolism and decreases the phosphorylation state of mTOR, eIF4E-BP1, and S6K1 in rat liver. | Life sciences 20060717 |
| Effects of ciprofibrate on testicular and adrenal steroidogenic enzymes in the rat. | Reproductive toxicology (Elmsford, N.Y.) 20060701 |
| Trace-level determination of pharmaceutical residues by LC-MS/MS in natural and treated waters. A pilot-survey study. | Analytical and bioanalytical chemistry 20060701 |
| Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. | Vascular pharmacology 20060701 |
| Dyslipidaemia, hypercoagulability and the metabolic syndrome. | Current vascular pharmacology 20060701 |
| Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome? | International journal of cardiology 20060616 |
| N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. | The Journal of nutritional biochemistry 20060601 |
| Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan). | Drug metabolism and disposition: the biological fate of chemicals 20060601 |
| Metabolomic study of cisplatin-induced nephrotoxicity. | Kidney international 20060601 |
| Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome. | British journal of clinical pharmacology 20060601 |
| [Nuclear receptors PPARalpha]. | Vnitrni lekarstvi 20060601 |
| PRIC320, a transcription coactivator, isolated from peroxisome proliferator-binding protein complex. | Biochemical and biophysical research communications 20060505 |
| Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticals. | Journal of pharmaceutical and biomedical analysis 20060503 |
| Lipid-lowering drugs. | Cellular and molecular life sciences : CMLS 20060501 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Apolipoproteins AI and B as therapeutic targets. | Journal of internal medicine 20060501 |
| Field of confusion: future prospects for fibrate therapy in cardiovascular disease. | Current atherosclerosis reports 20060501 |
| Bioactivation of carboxylic acid compounds by UDP-Glucuronosyltransferases to DNA-damaging intermediates: role of glycoxidation and oxidative stress in genotoxicity. | Chemical research in toxicology 20060501 |
| [Intensive cholesterol lowering therapy to reduce cardiovascular risk]. | Revista medica de Chile 20060501 |
| Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. | Reviews on recent clinical trials 20060501 |
| Statin safety: a systematic review. | The American journal of cardiology 20060417 |
| [Diabetic dyslipoproteinemia]. | MMW Fortschritte der Medizin 20060406 |
| HDL: the 'new' target of cardiovascular medicine. | International journal of cardiology 20060404 |
| Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. | Journal of hepatology 20060401 |
| Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia. | The Journal of nutrition 20060401 |
| [The fibrate-activated PPARalpha/p16INK4A pathway inhibits vascular smooth muscle cell proliferation and vascular occlusion]. | Medecine sciences : M/S 20060401 |
| [Hyperlipidemia]. | Nihon rinsho. Japanese journal of clinical medicine 20060401 |
| [Treatment of dyslipidemia: how and when to combine lipid lowering drugs]. | Arquivos brasileiros de endocrinologia e metabologia 20060401 |
| Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? | Circulation 20060328 |
| [Treatment of dyslipidemia in clinical practice]. | Orvosi hetilap 20060305 |
| The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. | The Science of the total environment 20060301 |
| Enantiomeric separation of some demethylated analogues of clofibric acid by capillary zone electrophoresis and nano-liquid chromatography. | Electrophoresis 20060301 |
| [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease]. | Investigacion clinica 20060301 |
| Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. | Current medical research and opinion 20060301 |
| [Fibrates, nicotinic acid preparations and muscular pain]. | Lakartidningen 20060301 |
| Is there evidence for the evidence-based guidelines for cardiovascular disease prevention in women? | Gender medicine 20060301 |
| Strategies for management and treatment of dyslipidemia in HIV/AIDS. | AIDS care 20060201 |
| Preliminary risk assessment of the lipid-regulating pharmaceutical clofibric acid, for three estuarine species. | Environmental research 20060201 |
| Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events. | Medical science monitor : international medical journal of experimental and clinical research 20060201 |
| 'Anti-inflammatory' drugs and their effects on type 2 diabetes. | Diabetes technology & therapeutics 20060201 |
| Effects of widely used pharmaceuticals and a detergent on oxidative stress biomarkers of the crustacean Artemia parthenogenetica. | Chemosphere 20060101 |
| Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects. | Medical hypotheses 20060101 |
| Lipid testing and lipid-lowering therapy in hospitalized ischemic stroke and transient ischemic attack patients: results from a statewide stroke registry. | Stroke 20060101 |
| Assessment of compliance with lipid guidelines in an academic medical center. | The Annals of pharmacotherapy 20060101 |
| Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. | Expert opinion on drug safety 20060101 |
| Low-density lipoprotein size and cardiovascular risk assessment. | QJM : monthly journal of the Association of Physicians 20060101 |
| Fibrates in combination with statins in the management of dyslipidemia. | Journal of clinical hypertension (Greenwich, Conn.) 20060101 |
| The metabolic syndrome--what is it and how should it be managed? | Journal of clinical hypertension (Greenwich, Conn.) 20060101 |
| Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20060101 |
| Flow cytometric assessment of peroxisome proliferation from frozen liver of fibrate-treated monkeys. | International journal of toxicology 20060101 |
| Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. | Drugs of today (Barcelona, Spain : 1998) 20060101 |
| Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells. | The international journal of biochemistry & cell biology 20060101 |
| Biologically relevant effects of mRNA amplification on gene expression profiles. | BMC bioinformatics 20060101 |
| Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs? | Journal of inherited metabolic disease 20060101 |
| 2-{3-[2-(4-chlorophenyl)ethoxy]phenylthio}-2-methylpropanoic acid: a fibrate-like compound with hypolipidemic and antidiabetic activity. | ChemMedChem 20060101 |
| Gene expression profiles in rat liver slices exposed to hepatocarcinogenic enzyme inducers, peroxisome proliferators, and 17alpha-ethinylestradiol. | International journal of toxicology 20060101 |
| Effect of clofibric acid on desmin and vimentin contents in rat myocardiocytes. | International journal of toxicology 20060101 |
| Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. | Cardiovascular diabetology 20060101 |
| [Clinical trials of statins and fibrates --a meta-analysis]. | Medicinski pregled 20060101 |
| Comparison of effects of fibrates in patients with hypertriglyceridemia. | Advances in therapy 20060101 |
| [Cardiovascular risk and possibilities of lowering it in patients with metabolic syndrome and type II diabetes mellitus. The role of fibrates]. | Kardiologiia 20060101 |
| Examination of Ligand-Dependent Coactivator Recruitment by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha). | PPAR research 20060101 |
| Cardiovascular disease: strategies for risk assessment and modification. | The Journal of cardiovascular nursing 20060101 |
| Prolonged statin administration does not act on the cell-mediated immunity of HIV-infected dyslipidemic patients treated with a steady and effective highly active antiretroviral therapy. A two-year prospective study of statin versus fibrate administration. | Journal of biological regulators and homeostatic agents 20060101 |
| [Synthesis and physico-chemical characterisation of some new derivatives of rutoside and clofibric acid]. | Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 20060101 |
| [Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care]. | Orvosi hetilap 20051225 |
| [New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)]. | MMW Fortschritte der Medizin 20051208 |
| Ciprofibrate stimulates the gastrin-producing cell by acting luminally on antral PPAR-alpha. | American journal of physiology. Gastrointestinal and liver physiology 20051201 |
| Role for fibrate therapy in diabetes: evidence before FIELD. | Current opinion in lipidology 20051201 |
| Fibrate prevents cisplatin-induced proximal tubule cell death. | Kidney international 20051201 |
| Household disposal of pharmaceuticals as a pathway for aquatic contamination in the United kingdom. | Environmental health perspectives 20051201 |
| Optimal lipid modification: the rationale for combination therapy. | Vascular health and risk management 20051201 |
| Fibrates inhibit aldose reductase activity in the forward and reverse reactions. | Biochemical pharmacology 20051125 |
| Phytol directly activates peroxisome proliferator-activated receptor alpha (PPARalpha) and regulates gene expression involved in lipid metabolism in PPARalpha-expressing HepG2 hepatocytes. | Biochemical and biophysical research communications 20051118 |
| Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future? | The American journal of cardiology 20051107 |
| Pharmacokinetic interactions between statins and fibrates. | The American journal of cardiology 20051107 |
| Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate. | AIDS (London, England) 20051104 |
| Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver. | Toxicological sciences : an official journal of the Society of Toxicology 20051101 |
| Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. | Hypertension (Dallas, Tex. : 1979) 20051101 |
| Hypertriglyceridemia-why, when and how should it be treated? | Zeitschrift fur Kardiologie 20051101 |
| Differential associations of statin and fibrate treatment with carotid arterial remodeling. | American journal of hypertension 20051101 |
| Therapeutical effects of PPAR agonists assessed by biomarker modulation. | Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20051101 |
| Orthogonal array designs for the optimization of liquid-liquid-liquid microextraction of nonsteroidal anti-inflammatory drugs combined with high-performance liquid chromatography-ultraviolet detection. | Journal of chromatography. A 20051028 |
| Statins and fibrates for preventing melanoma. | The Cochrane database of systematic reviews 20051019 |
| Fibrates and coronary risk reduction. | Atherosclerosis 20051001 |
| Effects of pharmaceuticals on Daphnia survival, growth, and reproduction. | Chemosphere 20051001 |
| High-density lipoprotein cholesterol: ready for prime time? | Singapore medical journal 20051001 |
| Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat? | Singapore medical journal 20051001 |
| Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. | Nature clinical practice. Cardiovascular medicine 20051001 |
| [Drug combinations: statins and fibrates]. | Arquivos brasileiros de cardiologia 20051001 |
| Clinical practice. Low HDL cholesterol levels. | The New England journal of medicine 20050922 |
| Synthesis and antiplatelet activity of thioaryloxyacids analogues of clofibric acid. | European journal of medicinal chemistry 20050901 |
| Pleiotropic effects of fibrates. | Current atherosclerosis reports 20050901 |
| Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. | Journal of cardiovascular pharmacology 20050901 |
| Differential antiatherogenic effects of PPARalpha versus PPARgamma agonists: should we be surprised? | Arteriosclerosis, thrombosis, and vascular biology 20050901 |
| Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis. | Italian heart journal : official journal of the Italian Federation of Cardiology 20050901 |
| Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. | Journal of medicinal chemistry 20050825 |
| Management of dyslipidemia in patients with complicated metabolic syndrome. | The American journal of cardiology 20050822 |
| Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. | American journal of physiology. Renal physiology 20050801 |
| Modulation of hepatic canalicular or basolateral transport proteins alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver. | Drug metabolism and disposition: the biological fate of chemicals 20050801 |
| Fate and mobility of pharmaceuticals in solid matrices. | Chemosphere 20050801 |
| Therapeutic roles of peroxisome proliferator-activated receptor agonists. | Diabetes 20050801 |
| Demystifying triglycerides: a practical approach for the clinician. | Cleveland Clinic journal of medicine 20050801 |
| Electrochemical determination of pharmaceuticals in spiked water samples. | Journal of hazardous materials 20050715 |
| Environmental fate of pharmaceuticals in water/sediment systems. | Environmental science & technology 20050715 |
| Behavior of selected pharmaceuticals in subsurface flow constructed wetlands: a pilot-scale study. | Environmental science & technology 20050715 |
| Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20050701 |
| Adiponectin receptor gene expression in human skeletal muscle cells is not regulated by fibrates and thiazolidinediones. | International journal of obesity (2005) 20050701 |
| Acute toxicity of widely used pharmaceuticals in aquatic species: Gambusia holbrooki, Artemia parthenogenetica and Tetraselmis chuii. | Ecotoxicology and environmental safety 20050701 |
| Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. | Current opinion in cardiology 20050701 |
| Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. | Xenobiotica; the fate of foreign compounds in biological systems 20050701 |
| Induction of overlapping genes by fasting and a peroxisome proliferator in pigs: evidence of functional PPARalpha in nonproliferating species. | American journal of physiology. Regulatory, integrative and comparative physiology 20050601 |
| Hepatic beta-oxidation and carnitine palmitoyltransferase I in neonatal pigs after dietary treatments of clofibric acid, isoproterenol, and medium-chain triglycerides. | American journal of physiology. Regulatory, integrative and comparative physiology 20050601 |
| Induction of pancreatic acinar cell proliferation by thyroid hormone. | The Journal of endocrinology 20050601 |
| Expression of cytochrome P450 enzymes in hepatic organoid reconstructed by rat small hepatocytes. | Journal of gastroenterology and hepatology 20050601 |
| [Significance of HDL cholesterol increase for the risk reduction. Methods of intervention. recommendations of experts]. | Kardiologia polska 20050601 |
| [Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates]. | Kardiologia polska 20050601 |
| [Influence of ACE inhibitors and fibrates on endothelial function]. | Kardiologia polska 20050601 |
| [Pleiotropic action of ACE-I and fibrates]. | Kardiologia polska 20050601 |
| [Combination pharmacotherapy therapy in the management of atherogenic dyslipidemia]. | Kardiologia polska 20050601 |
| PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia. | Neuroreport 20050531 |
| Differences in cell proliferation in rodent and human hepatic derived cell lines exposed to ciprofibrate. | Cancer letters 20050526 |
| The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'. | International journal of cardiology 20050525 |
| APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. | Neurology 20050510 |
| Occurrence of several acidic drugs in sewage treatment plants in Switzerland and risk assessment. | Water research 20050501 |
| The potential use of PPARalpha agonists as immunosuppressive agents. | Current opinion in investigational drugs (London, England : 2000) 20050501 |
| Regulation of palmitoyl-CoA chain elongation by clofibric acid in the liver of Zucker fa/fa rats. | Lipids 20050501 |
| Effect of different antilipidemic agents and diets on mortality: a systematic review. | Archives of internal medicine 20050411 |
| Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. | Molecular pharmacology 20050401 |
| Characterization of an acute molecular marker of nongenotoxic rodent hepatocarcinogenesis by gene expression profiling in a long term clofibric acid study. | Chemical research in toxicology 20050401 |
| Automorphosis of etiolated pea seedlings in space is simulated by a three-dimensional clinostat and the application of inhibitors of auxin polar transport. | Physiologia plantarum 20050401 |
| Rhabdomyolysis and lipid-lowering drugs. | JAMA 20050323 |
| Operational options to reduce matrix effects in liquid chromatography-electrospray ionization-mass spectrometry analysis of aqueous environmental samples. | Journal of chromatography. A 20050304 |
| Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein. | The Annals of pharmacotherapy 20050301 |
| Drugs for lipids. | Treatment guidelines from the Medical Letter 20050301 |
| Cross-flow microfiltration with periodical back-washing for photocatalytic degradation of pharmaceutical and diagnostic residues-evaluation of the long-term stability of the photocatalytic activity of TiO2. | Water research 20050301 |
| Management of dyslipidemia in women in the post-hormone therapy era. | Journal of general internal medicine 20050301 |
| Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. | Cardiovascular drugs and therapy 20050301 |
| Help for your cholesterol when statins won't do. If you are one of the many, but also one of the few.. | Harvard men's health watch 20050301 |
| Determination of pharmaceutical residues in waters by solid-phase extraction and large-volume on-line derivatization with gas chromatography-mass spectrometry. | Journal of chromatography. A 20050218 |
| Pretranslational upregulation of microsomal CYP4A in rat liver by intake of a high-sucrose, lipid-devoid diet containing orotic acid. | Biochemical pharmacology 20050215 |
| [Myopathies under therapy with lipid-lowering agents]. | Der Nervenarzt 20050201 |
| Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia. | Journal of cardiovascular pharmacology 20050201 |
| Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. | Current atherosclerosis reports 20050201 |
| [Dyslipidemia management in patients with impaired glucose tolerance]. | Nihon rinsho. Japanese journal of clinical medicine 20050201 |
| Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? | Current medical research and opinion 20050201 |
| Dissociation of branched-chain alpha-keto acid dehydrogenase kinase (BDK) from branched-chain alpha-keto acid dehydrogenase complex (BCKDC) by BDK inhibitors. | Journal of nutritional science and vitaminology 20050201 |
| Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. | Journal of the American College of Cardiology 20050118 |
| Photocatalytic degradation of carbamazepine, clofibric acid and iomeprol with P25 and Hombikat UV100 in the presence of natural organic matter (NOM) and other organic water constituents. | Water research 20050101 |
| Management of diabetic dyslipidemia: need for reappraisal of the goals. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101 |
| Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. | Pharmaceutical research 20050101 |
| [Cardiovascular system drugs. 9/12. Antilipemics--II. Fibrates and colestyramine]. | Soins; la revue de reference infirmiere 20050101 |
| AhR and PPARalpha: antagonistic effects on CYP2B and CYP3A, and additive inhibitory effects on CYP2C11. | Xenobiotica; the fate of foreign compounds in biological systems 20050101 |
| Diabetic dyslipidaemia: insights for optimizing patient management. | Current medical research and opinion 20050101 |
| Outcome studies in type 2 diabetes. | Current medical research and opinion 20050101 |
| Study of the liquid chromatography retention of some fibrate-type antihyperlipidemic drugs on C18 and CN columns: application for quantitation in pharmaceutical formulations. | Journal of AOAC International 20050101 |
| A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-agonists. | Journal of cellular and molecular medicine 20050101 |
| [Dyslipidaemia and diabetes mellitus]. | Revue medicale de Liege 20050101 |
| Mechanisms of calcium release from the sarcoplasmic reticulum in skeletal muscle. | Advances in experimental medicine and biology 20050101 |
| The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia. | Endothelium : journal of endothelial cell research 20050101 |
| Enzymatic examination of potential interaction between statins or fibrates and consumed Tricholoma equestre. | Przeglad lekarski 20050101 |
| Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles. | BMC genomics 20050101 |
| Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: comparison of the effects on morphological and biochemical parameters in liver and blood. | European journal of drug metabolism and pharmacokinetics 20050101 |
| Evaluation of the carcinogenic potential of clofibrate in the neonatal mouse. | International journal of toxicology 20050101 |
| Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101 |
| Hypertriglyceridemia, the coronary heart disease risk marker 'solved'. | Acta physiologica Hungarica 20050101 |
| [Variability in primary care drug prescription in 2003 in Castile-la Mancha, Spain]. | Revista espanola de salud publica 20050101 |
| [Fibrate-induced increase in serum creatinine levels: two cases]. | Therapie 20050101 |
| Suitability of hollow fibre liquid-phase microextraction for the determination of acidic pharmaceuticals in wastewater by liquid chromatography-electrospray tandem mass spectrometry without matrix effects. | Journal of chromatography. A 20041217 |
| Acute and chronic effects of clofibrate and clofibric acid on the enzymes acetylcholinesterase, lactate dehydrogenase and catalase of the mosquitofish, Gambusia holbrooki. | Chemosphere 20041201 |
| Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases. | Journal of epidemiology and community health 20041201 |
| Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. | JAMA 20041201 |
| Induction of phytohormones and differential gene expression in citrus flowers infected by the fungus Colletotrichum acutatum. | Molecular plant-microbe interactions : MPMI 20041201 |
| Therapeutic approaches to raising plasma HDL-cholesterol levels. | Nature clinical practice. Cardiovascular medicine 20041201 |
| [Low HDL-cholesterol, high triglycerides--well known but often ignored]. | Praxis 20041110 |
| Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. | The Journal of infection 20041101 |
| Clofibric and ethacrynic acids prevent experimental pyelonephritis by Escherichia coli in mice. | FEMS immunology and medical microbiology 20041101 |
| Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. | Thrombosis and haemostasis 20041101 |
| Down regulation of hepatic PPARalpha function by AhR ligand. | The Journal of veterinary medical science 20041101 |
| Peroxisome proliferator-activated receptors as regulators of lipid metabolism; tissue differential expression in adipose tissues during cold acclimatization and hibernation of jerboa (Jaculus orientalis). | Biochimie 20041101 |
| Pharmaceuticals and personal care products (PPCPs) and endocrine disrupting chemicals (EDCs) in stormwater canals and Bayou St. John in New Orleans, Louisiana, USA. | The Science of the total environment 20041015 |
| Activation of peroxisome proliferator-activated receptor alpha in rat spinal cord after peripheral noxious stimulation. | Neuroscience letters 20041007 |
| The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. | Atherosclerosis 20041001 |
| Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease. | Expert opinion on investigational drugs 20041001 |
| Determination of some acidic drugs in surface and sewage treatment plant waters by capillary electrophoresis-electrospray ionization-mass spectrometry. | Electrophoresis 20041001 |
| Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy. | Antiviral therapy 20041001 |
| Co-induction of methyltransferase Rv0560c by naphthoquinones and fibric acids suggests attenuation of isoprenoid quinone action in Mycobacterium tuberculosis. | Canadian journal of microbiology 20041001 |
| PPARalpha-dependent modulation of hepatic CYP1A by clofibric acid in rats. | Archives of toxicology 20040901 |
| Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. | Carcinogenesis 20040901 |
| Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. | Current opinion in cardiology 20040901 |
| Diabetes mellitus and unstable coronary artery disease: improved clinical outcome of coronary artery stenting in an era of glycoprotein IIb/IIIa inhibitors and lipid-lowering therapy. | Coronary artery disease 20040901 |
| Utility of currently available modes of therapy in reaching lipid goals. | The Journal of the American Osteopathic Association 20040901 |
| Coadministration of multidrug therapy to achieve lipid goals. | The Journal of the American Osteopathic Association 20040901 |
| Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. | Pharmaceutical research 20040901 |
| PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells. | Regulatory peptides 20040815 |
| Effects of vitamin E on the NF-kappaB pathway in rats treated with the peroxisome proliferator, ciprofibrate. | Toxicology and applied pharmacology 20040815 |
| Analysis by liquid chromatography-electrospray ionization tandem mass spectrometry and acute toxicity evaluation for beta-blockers and lipid-regulating agents in wastewater samples. | Journal of chromatography. A 20040813 |
| Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. | Fundamental & clinical pharmacology 20040801 |
| Protective behavior survey, West Nile virus, British Columbia. | Emerging infectious diseases 20040801 |
| Leaching behaviour of pharmaceuticals in soil-testing-systems: a part of an environmental risk assessment for groundwater protection. | The Science of the total environment 20040726 |
| PPARalpha agonists clofibrate and gemfibrozil inhibit cell growth, down-regulate hCG and up-regulate progesterone secretions in immortalized human trophoblast cells. | Biochemical pharmacology 20040715 |
| Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes. | Biochimica et biophysica acta 20040705 |
| Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation. | The Journal of biological chemistry 20040702 |
| The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions. | The Journal of biological chemistry 20040702 |
| Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications. | Biochemical and biophysical research communications 20040702 |
| Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20040601 |
| Statin and fibrate associated myopathy: study of eight patients. | Arquivos de neuro-psiquiatria 20040601 |
| Sexually dimorphic metabolism of branched-chain lipids in C57BL/6J mice. | Journal of lipid research 20040501 |
| Environmental risk assessment of six human pharmaceuticals: are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment? | Environmental toxicology and chemistry 20040501 |
| Highlights from the 74th Congress of the European Atherosclerosis Society. | Timely topics in medicine. Cardiovascular diseases 20040501 |
| Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes. | Toxicological sciences : an official journal of the Society of Toxicology 20040401 |
| Regulation of apoptosis by peroxisome proliferators. | Toxicology letters 20040401 |
| Properties of an alginate gel bead containing a chitosan-drug salt. | Biological & pharmaceutical bulletin 20040301 |
| Liquid chromatography with triple-quadrupole or quadrupole-time of flight mass spectrometry for screening and confirmation of residues of pharmaceuticals in water. | Analytical and bioanalytical chemistry 20040201 |
| Evaluation of the dermal subchronic toxicity of phenoxyethyl isobutyrate in the rat. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20040201 |
| Kinetic study of photocatalytic degradation of carbamazepine, clofibric acid, iomeprol and iopromide assisted by different TiO2 materials--determination of intermediates and reaction pathways. | Water research 20040201 |
| Two-step liquid-liquid-liquid microextraction of nonsteroidal antiinflammatory drugs in wastewater. | Analytical chemistry 20040101 |
| In vitro reactivity of carboxylic acid-CoA thioesters with glutathione. | Chemical research in toxicology 20040101 |
| Miniaturized fluorescent RNA dot blot method for rapid quantitation of gene expression. | BMC biotechnology 20040101 |
| Application of UV-derivative spectra for determination of four antihyperlipidaemic drugs in pharmaceutical formulations. | Acta poloniae pharmaceutica 20040101 |
| Role of fibric acid derivatives in the management of risk factors for coronary heart disease. | Drugs 20040101 |
| Transport of pharmaceutically active compounds in saturated laboratory columns. | Ground water 20040101 |
| Effects of advanced oxidation processes (AOPs) on the toxicity of a mixture of pharmaceuticals. | Water science and technology : a journal of the International Association on Water Pollution Research 20040101 |
| Toxic effect of pharmaceuticals on methanogenesis. | Water science and technology : a journal of the International Association on Water Pollution Research 20040101 |
| Comparative effects of lipid-lowering therapies. | Progress in cardiovascular diseases 20040101 |
| Overexpression of SR-BI by adenoviral vector reverses the fibrateinduced hypercholesterolemia of apolipoprotein E-deficient mice. | The Journal of biological chemistry 20031226 |
| Determination of acidic pharmaceuticals, antibiotics and ivermectin in river sediment using liquid chromatography-tandem mass spectrometry. | Journal of chromatography. A 20031222 |
| Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? | Current opinion in lipidology 20031201 |
| Liver gene expression profiles of rats treated with clofibric acid: comparison of whole liver and laser capture microdissected liver. | The American journal of pathology 20031201 |
| Occurrence of neutral and acidic drugs in the effluents of Canadian sewage treatment plants. | Environmental toxicology and chemistry 20031201 |
| Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada. | Environmental toxicology and chemistry 20031201 |
| p-Chlorophenoxyisobutyric acid impairs auxin response in Arabidopsis root. | Plant physiology 20031101 |
| Ozonation and H2O2/UV treatment of clofibric acid in water: a kinetic investigation. | Journal of hazardous materials 20031031 |
| Determination of selected human pharmaceutical compounds in effluent and surface water samples by high-performance liquid chromatography-electrospray tandem mass spectrometry. | Journal of chromatography. A 20031010 |
| Cell proliferation and apoptosis are altered in mice deficient in the NF-kappaB p50 subunit after treatment with the peroxisome proliferator ciprofibrate. | Toxicological sciences : an official journal of the Society of Toxicology 20031001 |
| Pharmaceutical and personal care products in sewage treatment works. | Journal of environmental monitoring : JEM 20031001 |
| Hypertriglyceridemia increases mitochondrial resting respiration and susceptibility to permeability transition. | Journal of bioenergetics and biomembranes 20031001 |
| Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-alpha agonist ciprofibrate. | Physiological genomics 20030929 |
| Simultaneous determination of clofibrate and its active metabolite clofibric acid in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet absorbance detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030905 |
| Fate of pharmaceuticals--photodegradation by simulated solar UV-light. | Chemosphere 20030901 |
| Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. | Toxicology and applied pharmacology 20030901 |
| Ethylene promotes the induction by auxin of the cortical microtubule randomization required for low-pH-induced root hair initiation in lettuce (Lactuca sativa L.) seedlings. | Plant & cell physiology 20030901 |
| Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20030901 |
| The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. | The Biochemical journal 20030801 |
| Chromatin sphingomyelin changes in cell proliferation and/or apoptosis induced by ciprofibrate. | Journal of cellular physiology 20030801 |
| Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. | The Journal of clinical endocrinology and metabolism 20030801 |
| [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates]. | Casopis lekaru ceskych 20030801 |
| Reshaping the dyslipidemia management paradigm. | Postgraduate medicine 20030801 |
| CHD risk equivalents and the metabolic syndrome. Trial evidence supports aggressive management. | Postgraduate medicine 20030801 |
| Pharmaceuticals and personal care products (PPCPs) in surface and treated waters of Louisiana, USA and Ontario, Canada. | The Science of the total environment 20030720 |
| Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac. | Ecotoxicology and environmental safety 20030701 |
| Fibrates and renal function. | Clinical nephrology 20030701 |
| LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit? | Diabetes research and clinical practice 20030701 |
| Short-term tests with a pilot sewage plant and biofilm reactors for the biological degradation of the pharmaceutical compounds clofibric acid, ibuprofen, and diclofenac. | The Science of the total environment 20030620 |
| Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells. | The Journal of pharmacology and experimental therapeutics 20030601 |
| Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins. | Acta cardiologica 20030601 |
| [Ciprofibrate-induced acute cholestatic hepatitis]. | Annales d'endocrinologie 20030601 |
| UDP-glucuronosyltransferase-dependent bioactivation of clofibric acid to a DNA-damaging intermediate in mouse hepatocytes. | Chemico-biological interactions 20030506 |
| Identification of coenzyme A-related tolmetin metabolites in rats: relationship with reactive drug metabolites. | Xenobiotica; the fate of foreign compounds in biological systems 20030501 |
| Molecular profiling of hepatocellular carcinomas developing spontaneously in acyl-CoA oxidase deficient mice: comparison with liver tumors induced in wild-type mice by a peroxisome proliferator and a genotoxic carcinogen. | Carcinogenesis 20030501 |
| Regulation by carbohydrate and clofibric acid of palmitoyl-CoA chain elongation in the liver of rats. | Lipids 20030501 |
| Determination of polar pharmaceuticals in sewage water of Greece by gas chromatography-mass spectrometry. | Chemosphere 20030401 |
| Occurrence and fate of carbamazepine, clofibric acid, diclofenac, ibuprofen, ketoprofen, and naproxen in surface waters. | Environmental science & technology 20030315 |
| Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment. | Chemosphere 20030301 |
| Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. | Naunyn-Schmiedeberg's archives of pharmacology 20030301 |
| Fibrates and medroxyprogesterone acetate induce apoptosis of primary Burkitt's lymphoma cells and cell lines: potential for applying old drugs to a new disease. | Leukemia 20030301 |
| Antral G cells in rats during dosing with a PPAR alpha agonist: a morphometric and immunocytochemical study. | Medical electron microscopy : official journal of the Clinical Electron Microscopy Society of Japan 20030301 |
| What future for combination therapies? | International journal of clinical practice. Supplement 20030301 |
| Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. | The Biochemical journal 20030201 |
| Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia. | American journal of physiology. Lung cellular and molecular physiology 20030201 |
| Fibrates and C-reactive protein. | Clinica chimica acta; international journal of clinical chemistry 20030201 |
| Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs. | International immunopharmacology 20030201 |
| Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. | Blood 20030115 |
| Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. | Gastroenterology 20030101 |
| Different effects of the liver mitogens triiodo-thyronine and ciprofibrate on the development of rat hepatocellular carcinoma. | Toxicologic pathology 20030101 |
| [Conjugation reactions of ciprofibrate with human and laboratory animals]. | Arzneimittel-Forschung 20030101 |
| Evidence of cytochrome P450-catalyzed cleavage of the ether bond of phenoxybutyrate herbicides in Rhodococcus erythropolis K2-3. | Biodegradation 20030101 |
| A comprehensive description of muscle symptoms associated with lipid-lowering drugs. | Cardiovascular drugs and therapy 20030101 |
| Clofibric acid stimulates branched-chain amino acid catabolism by three mechanisms. | Archives of biochemistry and biophysics 20021115 |
| Effects of various fibrates on serum alkaline phosphatase activity. | Atherosclerosis 20021101 |
| In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. | Drug metabolism and disposition: the biological fate of chemicals 20021101 |
| Dysbetalipoproteinaemia--clinical and pathophysiological features. | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20021101 |
| Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation. | American journal of physiology. Cell physiology 20021001 |
| Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. | Journal of cardiovascular pharmacology and therapeutics 20021001 |
| PPAR alpha stimulates the rat gastrin-producing cell. | Molecular and cellular endocrinology 20020930 |
| Differentiated properties of hepatocytes induced from pancreatic cells. | Hepatology (Baltimore, Md.) 20020901 |
| Removal of pharmaceuticals during drinking water treatment. | Environmental science & technology 20020901 |
| Current drug treatments for lipid management. | Managed care (Langhorne, Pa.) 20020901 |
| Drugs and personal care products as ubiquitous pollutants: occurrence and distribution of clofibric acid, caffeine and DEET in the North Sea. | The Science of the total environment 20020805 |
| HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. | Clinical science (London, England : 1979) 20020801 |
| Ciglitazone inhibits plasmin-induced proinflammatory monocyte activation via modulation of p38 MAP kinase activity. | Thrombosis and haemostasis 20020801 |
| Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-kappaB activation. | European journal of pharmacology 20020712 |
| Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. | Pharmacology & therapeutics 20020701 |
| Detection of pharmaceutical contaminations of river, pond, and tap water from Cologne (Germany) and surroundings. | International journal of hygiene and environmental health 20020701 |
| Molecular modelling of the peroxisome proliferator-activated receptor alpha (PPAR alpha) from human, rat and mouse, based on homology with the human PPAR gamma crystal structure. | Toxicology in vitro : an international journal published in association with BIBRA 20020601 |
| PPARalpha suppresses insulin secretion and induces UCP2 in insulinoma cells. | Journal of lipid research 20020601 |
| Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. | Toxicology letters 20020510 |
| Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR. | American journal of physiology. Cell physiology 20020501 |
| Analysis of acidic drugs in the effluents of sewage treatment plants using liquid chromatography-electrospray ionization tandem mass spectrometry. | Journal of chromatography. A 20020405 |
| The peroxisome proliferator-activated receptor alpha-selective activator ciprofibrate upregulates expression of genes encoding fatty acid oxidation and ketogenesis enzymes in rat brain. | Neuropharmacology 20020401 |
| Cytochemical and biochemical demonstration of an ATPase in membranes of human peroxisomes. | The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 20020301 |
| Analysis of serious adverse events. Lipid-lowering therapy revisited. | Canadian family physician Medecin de famille canadien 20020301 |
| Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. | The American journal of cardiology 20020215 |
| Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation. | Free radical biology & medicine 20020201 |
| Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. | Journal of cardiovascular risk 20020201 |
| Lipids in type 2 diabetes. | Seminars in vascular medicine 20020201 |
| Clofibric acid down-regulation of metallothionein IIA in HepG2 human hepatoma cells. | Biochemical pharmacology 20020115 |
| Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. | Biochemical and biophysical research communications 20020111 |
| Studies on the reactivity of clofibryl-S-acyl-CoA thioester with glutathione in vitro. | Drug metabolism and disposition: the biological fate of chemicals 20020101 |
| Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. | The Journal of pharmacology and experimental therapeutics 20020101 |
| Effect of ciprofibrate on C-reactive protein and fibrinogen levels. | Angiology 20020101 |
| Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor alpha ligand in rats. | In vivo (Athens, Greece) 20020101 |
| Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia. | Current medical research and opinion 20020101 |
| Use of dominant negative nuclear receptors to study xenobiotic-inducible gene expression in primary cultured hepatocytes. | Journal of pharmacological and toxicological methods 20020101 |
| Nafenopin-, ciprofibroyl-, and palmitoyl-CoA conjugation in vitro: kinetic and molecular characterization of marmoset liver microsomes and expressed MLCL1. | Archives of biochemistry and biophysics 20011201 |
| Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. | International journal of clinical pharmacology and therapeutics 20011201 |
| Occurrence of pharmaceutical contaminants and screening of treatment alternatives for southeastern Louisiana. | Annals of the New York Academy of Sciences 20011201 |
| Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects. | Journal of cardiovascular pharmacology 20011101 |
| Differential induction of peroxisomal beta-oxidation enzymes by clofibric acid and aspirin in piglet tissues. | American journal of physiology. Regulatory, integrative and comparative physiology 20011101 |
| Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. | Arteriosclerosis, thrombosis, and vascular biology 20011101 |
| Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. | Metabolism: clinical and experimental 20011101 |
| Metabolic alterations by clofibric acid in the formation of molecular species of phosphatidylcholine in rat liver. | Biochemical pharmacology 20011001 |
| Properties of Ca(2+) release induced by clofibric acid from the sarcoplasmic reticulum of mouse skeletal muscle fibres. | British journal of pharmacology 20011001 |
| Effects of dantrolene and its derivatives on Ca(2+) release from the sarcoplasmic reticulum of mouse skeletal muscle fibres. | British journal of pharmacology 20011001 |
| Carboxylic acids and skeletal muscle chloride channel conductance: effects on the biological activity induced by the introduction of an aryloxyalkyl group alpha to the carboxylic function of 4-chloro-phenoxyacetic acid. | Farmaco (Societa chimica italiana : 1989) 20011001 |
| Selective degradation of ibuprofen and clofibric acid in two model river biofilm systems. | Water research 20010901 |
| Drastic reduction of the slow gate of human muscle chloride channel (ClC-1) by mutation C277S. | The Journal of physiology 20010801 |
| Activation of the activator protein-1 by the peroxisome proliferator clofibric acid in rat H4IIEC3 hepatoma cells. | Toxicology and applied pharmacology 20010801 |
| Interaction of gamma-glutamyltranspeptidase with clofibryl-S-acyl-glutathione in vitro and in vivo in rat. | Chemical research in toxicology 20010801 |
| Fibrate-induced increase in blood urea and creatinine. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010701 |
| Fibrate treatment can increase serum creatinine levels. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010601 |
| Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. | Metabolism: clinical and experimental 20010601 |
| Suppression of hepatocyte nuclear factor-4alpha by acyl-CoA thioesters of hypolipidemic peroxisome proliferators. | Biochemical pharmacology 20010501 |
| [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia]. | Orvosi hetilap 20010415 |
| Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism. | Diabetes, obesity & metabolism 20010401 |
| Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species. | The Journal of pharmacy and pharmacology 20010401 |
| Homocysteine elevation with fibrates: is it a class effect? | The Israel Medical Association journal : IMAJ 20010401 |
| Simultaneous quantification of neutral and acidic pharmaceuticals and pesticides at the low-ng/l level in surface and waste water. | Journal of chromatography. A 20010316 |
| Assessment of P450 induction in the marmoset monkey using targeted anti-peptide antibodies. | Biochimica et biophysica acta 20010309 |
| Statin-fibrate combinations in patients with combined hyperlipedemia. | Atherosclerosis 20010301 |
| Carboxylic acids and skeletal muscle chloride channel conductance: effects on the biological activity induced by the introduction of methyl groups on the aromatic ring of chiral alpha-(4-chloro-phenoxy)alkanoic acids. | Farmaco (Societa chimica italiana : 1989) 20010301 |
| Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry. | Journal of chromatography. A 20010223 |
| Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. | Atherosclerosis 20010201 |
| Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells. | Biochemical pharmacology 20010201 |
| Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20010201 |
| Diabetes: statins, fibrates, or both? | Current atherosclerosis reports 20010101 |
| The role of fibric acids in atherosclerosis. | Current atherosclerosis reports 20010101 |
| Treatment of dyslipoproteinemia in the metabolic syndrome. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20010101 |
| Statin-fibrate combination therapy. | The Annals of pharmacotherapy 20010101 |
| Hypertriglyceridemia: associated risks and effect of drug treatment. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20010101 |
| Drug treatment of combined hyperlipidemia. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20010101 |
| Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20001201 |
| CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. | Drug metabolism and disposition: the biological fate of chemicals 20001101 |
| Pharmacological characterization of chloride channels belonging to the ClC family by the use of chiral clofibric acid derivatives. | Molecular pharmacology 20000901 |
| Detection of chemical-induced differential expression of rat hepatic cytochrome P450 mRNA transcripts using branched DNA signal amplification technology. | Drug metabolism and disposition: the biological fate of chemicals 20000501 |
| Differential induction of hepatic drug-metabolizing enzymes by fenvaleric acid in male rats. | Toxicological sciences : an official journal of the Society of Toxicology 19991201 |
| Fibrates, dyslipoproteinaemia and cardiovascular disease. | Current opinion in lipidology 19991201 |
| A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity. | Journal of medicinal chemistry 19990923 |
| Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. | Arteriosclerosis, thrombosis, and vascular biology 19990601 |
| Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. | International journal of cardiology 19990601 |
| Insulin differentially affects xenobiotic-enhanced, cytochrome P-450 (CYP)2E1, CYP2B, CYP3A, and CYP4A expression in primary cultured rat hepatocytes. | The Journal of pharmacology and experimental therapeutics 19990501 |
| Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. | Blood 19990501 |
| Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha. | Thrombosis and haemostasis 19981201 |
| Mechanisms of peroxisome proliferation by perfluorooctanoic acid and endogenous fatty acids. | General pharmacology 19980801 |
| Clinical pharmacokinetics of fibric acid derivatives (fibrates). | Clinical pharmacokinetics 19980201 |
| The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48-containing lipoproteins. | Biochimica et biophysica acta 19961111 |
| Growth regulation by peroxisome proliferators: opposing activities in early and late G1. | Cancer research 19960715 |
| Oltipraz-mediated changes in aflatoxin B(1) biotransformation in rat liver: implications for human chemointervention. | Cancer research 19960515 |
| Flow cytometric analysis of neoplastic nodules and hepatocellular carcinomas induced by ciprofibrate in the rat. | British journal of cancer 19960101 |
| [Rhabdomyolysis and unexplained malaise. Role of combination of ciprofibrate and norfloxacin]. | La Revue de medecine interne 19960101 |
| Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. | Journal of lipid research 19951201 |
| Currently available hypolipidaemic drugs and future therapeutic developments. | Bailliere's clinical endocrinology and metabolism 19951001 |
| The effects of diquat and ciprofibrate on mRNA expression and catalytic activities of hepatic xenobiotic metabolizing and antioxidant enzymes in rat liver. | Toxicology and applied pharmacology 19950901 |
| Xenobiotic-enhanced expression of cytochrome P450 2E1 and 2B1/2B2 in primary cultured rat hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 19950701 |
| The herbicide dicamba (2-methoxy-3,6-dichlorobenzoic acid) is a peroxisome proliferator in rats. | Fundamental and applied toxicology : official journal of the Society of Toxicology 19950601 |
| Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cell proliferation and toxicity in Sprague-Dawley rats. | Carcinogenesis 19941201 |
| The effects of clofibrate and bezafibrate on cholesterol metabolism in the liver of the male rat. | Lipids 19941101 |
| Antihyperlipidaemic agents. Drug interactions of clinical significance. | Drug safety 19941101 |
| A recombinant phenobarbital-inducible rat liver UDP-glucuronosyltransferase (UDP-glucuronosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine, phenols, and carboxylic acids. | Molecular pharmacology 19940101 |
| Further studies on the involvement of selenium in peroxisome proliferation in rat liver. Comparison of effects with clofibric acid and perfluorooctanoic acid and the pharmacokinetics of [14C]clofibrate. | Biochemical pharmacology 19931117 |
| Coordinate induction of acyl-CoA binding protein, fatty acid binding protein and peroxisomal beta-oxidation by peroxisome proliferators. | Biochimica et biophysica acta 19930606 |
| Reinduction of the hypnotic effects of thiopental with NSAIDs by decreasing thiopental plasma protein binding in humans. | Acta anaesthesiologica Scandinavica 19930401 |
| Lack of peroxisomal enzyme inducibility in rat hepatic preneoplastic lesions induced by mutagenic carcinogens: contrasted expression of glutathione S-transferase P form and enoyl CoA hydratase. | Carcinogenesis 19930301 |
| Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. | The Journal of pharmacology and experimental therapeutics 19930101 |
| Analysis of activated protooncogenes in B6C3F1 mouse liver tumors induced by ciprofibrate, a potent peroxisome proliferator. | Carcinogenesis 19930101 |
| Mechanism of action of fibrates. | Postgraduate medical journal 19930101 |
| Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. | Nature 19920827 |
| Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. | Biochimica et biophysica acta 19920709 |
| Plasma levels of HGF in rats treated with tumor promoters. | Carcinogenesis 19920101 |
| Peroxisome proliferation in neoplastic nodules and hepatocellular carcinomas induced by ciprofibrate in the rat. | Experimental pathology 19910101 |
| On the mechanism of the hepatocarcinogenicity of peroxisome proliferators. | Chemico-biological interactions 19910101 |
| Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. | Journal of clinical pharmacology 19910101 |
| Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation. | Biochemical pharmacology 19900901 |
| Peroxisome proliferator-induced alterations in the expression and modification of rat hepatocyte plasma membrane proteins. | Cancer research 19900201 |
| Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism. | Biochimica et biophysica acta 19881104 |
| Lack of expression of glutathione-S-transferase P, gamma-glutamyl transpeptidase, and alpha-fetoprotein messenger RNAs in liver tumors induced by peroxisome proliferators. | Cancer research 19880901 |
| Interactions of inhibitors of carnitine palmitoyltransferase I and fibrates in cultured hepatocytes. | The Biochemical journal 19880701 |
| Absence of gamma-glutamyltranspeptidase activity in lung metastasis in rats with hepatocellular carcinomas induced by ciprofibrate, a peroxisome proliferator. | Cancer letters 19871201 |
| Peroxisome proliferator-induced hepatocarcinogenesis: levels of activating and detoxifying enzymes in hepatocellular carcinomas induced by ciprofibrate. | Carcinogenesis 19870101 |
| Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report. | Acta neuropathologica 19850101 |
| Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics. | Atherosclerosis 19820601 |
| [Clofibrate therapy--current status from a gerontological viewpoint]. | Zeitschrift fur Alternsforschung 19820101 |